Navigation Links
CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing
Date:6/26/2009

Cutting Edge System Will Offer Clients Customized Solutions to Complex Localization Needs

Beijing, China (PRWEB) June 26, 2009 -- CSOFT International Ltd., a leading provider of multilingual localization, testing, and outsourced software development for the global market, announced the upcoming launch of L10NPRO 3.0 at its 6th Annual Worldwide Operations Summit in Beijing, China. L10NPRO 3.0, scheduled for release this fall, is designed to be a practical, no hassle localization management enterprise system that incorporates all areas of a typical localization workflow, such as quotation, TM leverage, project tracking, review, delivery and invoicing.

"CSOFT's L10NPRO will offer streamlined solutions for every day localization challenges," said Shunee Yee, CEO of CSOFT International, Ltd. "L10NPRO is highly automated and straightforward to use so it will be much more nimble than other similar systems."

One of the important features of CSOFT's L10NPRO is the Engineering Memory (EM) and the ability for the system to "learn" in order to process various file formats. EM is a cutting-edge technology developed within CSOFT that borrows the concept of Translation Memory (TM) technology.
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing
CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing
(Date:11/24/2009)...24 NeurogesX, Inc. (Nasd...n developing and commercializing novel pain manage...no, President and Chief Executive Officer, is sche...Health Care Conference, to be held December 1-2, 2...York. ,, Mr. DiTonno and Stephen Ghiglieri, Ch...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...Newswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ... company, today,announced that it has submitted a ...rase alfa, the company,s enzyme replacement therap...er disease. This is the third marketing,applicatio...with previous,submissions in the United States and...
(Date:11/24/2009)...r 24 Health Robotics today announc... with a group of selected,investors. This recently...he,name Health Robotics Canada, Inc. and will mark...m of the Future concept, which includes the,revolu...T(TM), and OMM(TM).,Health Robotics Canada Inc. wi...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) to...e 3 clinical programs, Unit Dose Budesonide (UDB) ... treatment of migraine. For UDB, all,patients hav...itial Phase 3,clinical trial, and for MAP0004, the...in its initial Phase 3 clinical trial by the end o...
...of Schedule , , ST. LOUIS and RICHMOND, Calif., ... ) today announced it has reached a major producti...h Sigma-Aldrich Corporation (Nasdaq: SIAL ) to c...for research applications. The milestone triggers ...ng this production milestone more than one year ah...
...sset, Inc. (Nasdaq: VRUS ) announced today that ...reed with the FDA on the final design for a phase ...atitis C (HCV), slated to initiate in the first qu...8 is advancing into a large phase 2b trial," state...ical Officer. "R7128 is the most advanced nucleosi...
Other Biology Technology:MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 2Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 3Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
(Date:11/24/2009)...nd the American College of Medical Toxicology (ACM...publication of the Journal of Medical Toxicology ...g in March 2010. It was previously published by t...rnal of Medical Toxicology , an international, pee...science and practice of medical toxicology. The q...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Strep B Seems to Trick Immune System 51448 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 1National Trauma Institute Announces 15th Annual Trauma Symposium in San Antonio August 31 September 1 51444 2
...ered that two microRNA (miRNA) molecules help cont...of B-cell chronic lymphocytic leukemia (B-CLL), th...r findings, published in the December 15 issue of ...ing as powerful regulators of gene expression in c... drug treatment, the investigators say. , In t...
...blem could be eliminated simply by dusting slag on...& Industry, the magazine of the SCI. , In the ...f damage annually. , Researcher David Cowen and...t applying slag to wheat growing in greenhouses ha...orporate the silica and express it as spiky struct...
... of plants to defend themselves by accumulating hi...me insects, and that such adaptation potentially e...ites may in turn evolve to deal with high levels o...zabeth Pilon-Smits of Colorado State University an...rnia, Berkeley, appear in the November 21st issue ...
Other Biology News:Pair of microRNA molecules controls major oncogene in most common leukemia 2New moth variety disarms plants guarded by selenium 2
Rabbit Anti-Mouse SHPRH Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Tyrosine Hydroxylase, phospho (Ser40) Polyclonal Antibody, Unconjugated from IMGENEX
NF kappa B Related Sampler Kit from BD Biosciences Pharmingen
Biology Products: